TY  - CONF

T1  - A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib.

JO  - BLOOD

PY  - 2007/11/16

AU  - Pilgrim H

AU  - Jewitt K

AU  - Ward S

ED  - 

VL  - 110

IS  - 11

SP  - 376B

EP  - 376B

Y2  - 2024/12/21

ER  -